Benzinga··Vandana SinghUnited Therapeutics' Ralinepag Shows 55% Drop in PAH Worsening, Stock Soars
United Therapeutics ($UTHR) stock rallies 3.98% after Phase 3 trial shows ralinepag reduces PAH worsening 55%, with FDA filing targeted for mid-2026.
UTHRFDA approvalPhase 3 trial